{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T13:45:37Z","timestamp":1785764737135,"version":"3.56.0"},"reference-count":102,"publisher":"American Association for the Advancement of Science (AAAS)","issue":"1","funder":[{"DOI":"10.13039\/501100003825","name":"Magyar Tudom\u00e1nyos Akad\u00e9mia","doi-asserted-by":"publisher","award":["J\u00e1nos Bolyai Research Scholarship"],"award-info":[{"award-number":["J\u00e1nos Bolyai Research Scholarship"]}],"id":[{"id":"10.13039\/501100003825","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018818","name":"National Research, Development and Innovation Office","doi-asserted-by":"publisher","award":["PharmaLab, RRF-2.3.1-21-2022-00015"],"award-info":[{"award-number":["PharmaLab, RRF-2.3.1-21-2022-00015"]}],"id":[{"id":"10.13039\/501100018818","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011019","name":"Nemzeti Kutat\u00e1si Fejleszt\u00e9si \u00e9s Innov\u00e1ci\u00f3s Hivatal","doi-asserted-by":"publisher","award":["SNN 139323"],"award-info":[{"award-number":["SNN 139323"]}],"id":[{"id":"10.13039\/501100011019","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012550","name":"Nemzeti Kutat\u00e1si, Fejleszt\u00e9si \u00e9s Innovaci\u00f3s Alap","doi-asserted-by":"publisher","award":["TKP2021-EGA"],"award-info":[{"award-number":["TKP2021-EGA"]}],"id":[{"id":"10.13039\/501100012550","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["spj.science.org"],"crossmark-restriction":true},"short-container-title":["Comput Struct Biotechnol J"],"published-print":{"date-parts":[[2026,3,1]]},"abstract":"<jats:p>The rise of rapidly mutating viruses poses growing challenges for drug developers in the fight against antiviral resistance. Viral ion channels generally have low mutation rates and are therefore considered emerging targets for a sustainable solution to the problem of resistance. This study reports the redesign of scaffolds for drug candidates targeting viral ion channels. The redesign was powered by a combination of a computational docking protocol that accounts for water molecules (HydroDock) and a subsequent quantum mechanics-based scoring (QMH-L) of the drug candidates. Extending the antiviral amantadine led to new compounds that better match the alternating hydrophobic and hydrophilic patterns of the inner walls of ion channels\u2014a common feature across many viruses. Simplifying the structure yielded a cyclohexylamine-based minimalist scaffold that demonstrates improved antiviral activity compared to other agents such as amantadine and arterolane. SARS-CoV-2 variants served as test systems in laboratory experiments. The new molecular scaffolds presented here provide a strong foundation for designing potent viral ion channel blockers, helping to fill the drug pipeline.<\/jats:p>","DOI":"10.34133\/csbj.0188","type":"journal-article","created":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T08:32:24Z","timestamp":1784017944000},"update-policy":"https:\/\/doi.org\/10.34133\/aaas_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["The Redesign of the Molecular Scaffold of Viral Ion Channel Blockers"],"prefix":"10.34133","volume":"35","author":[{"given":"Bal\u00e1zs Zolt\u00e1n","family":"Zsid\u00f3","sequence":"first","affiliation":[{"name":"Pharmacoinformatics Unit, Department of Pharmacology and Pharmacotherapy, Medical School, \rUniversity of P\u00e9cs, 7624 P\u00e9cs, Hungary."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erzs\u00e9bet","family":"Merny\u00e1k","sequence":"additional","affiliation":[{"name":"Institute of Pharmacognosy, \rUniversity of Szeged, H-6720 Szeged, Hungary."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-1176-5529","authenticated-orcid":false,"given":"Zolt\u00e1n","family":"Kopasz","sequence":"additional","affiliation":[{"name":"National Laboratory of Virology, Szent\u00e1gothai Research Centre, \rUniversity of P\u00e9cs, 7624 P\u00e9cs, Hungary."},{"name":"Institute of Biology, Faculty of Sciences, \rUniversity of P\u00e9cs, 7624 P\u00e9cs, Hungary."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fanni","family":"F\u00f6ldes","sequence":"additional","affiliation":[{"name":"National Laboratory of Virology, Szent\u00e1gothai Research Centre, \rUniversity of P\u00e9cs, 7624 P\u00e9cs, Hungary."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krisztina","family":"Leiner","sequence":"additional","affiliation":[{"name":"National Laboratory of Virology, Szent\u00e1gothai Research Centre, \rUniversity of P\u00e9cs, 7624 P\u00e9cs, Hungary."},{"name":"Institute of Biology, Faculty of Sciences, \rUniversity of P\u00e9cs, 7624 P\u00e9cs, Hungary."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00f3nika","family":"Madai","sequence":"additional","affiliation":[{"name":"National Laboratory of Virology, Szent\u00e1gothai Research Centre, \rUniversity of P\u00e9cs, 7624 P\u00e9cs, Hungary."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigitta","family":"Zana","sequence":"additional","affiliation":[{"name":"National Laboratory of Virology, Szent\u00e1gothai Research Centre, \rUniversity of P\u00e9cs, 7624 P\u00e9cs, Hungary."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anett","family":"Kuczmog","sequence":"additional","affiliation":[{"name":"National Laboratory of Virology, Szent\u00e1gothai Research Centre, \rUniversity of P\u00e9cs, 7624 P\u00e9cs, Hungary."},{"name":"Institute of Biology, Faculty of Sciences, \rUniversity of P\u00e9cs, 7624 P\u00e9cs, Hungary."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8013-971X","authenticated-orcid":true,"given":"Csaba","family":"Het\u00e9nyi","sequence":"additional","affiliation":[{"name":"Pharmacoinformatics Unit, Department of Pharmacology and Pharmacotherapy, Medical School, \rUniversity of P\u00e9cs, 7624 P\u00e9cs, Hungary."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"221","published-online":{"date-parts":[[2026,8,3]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-018-0327-4"},{"issue":"1","key":"e_1_3_4_3_2","doi-asserted-by":"crossref","DOI":"10.1093\/ve\/vew014","article-title":"Antiviral drug resistance as an adaptive process","volume":"2","author":"Irwin KK","year":"2016","unstructured":"Irwin KK, Renzette N, Kowalik TF, Jensen JD. Antiviral drug resistance as an adaptive process. Virus Evol. 2016;2(1): Article vew014.","journal-title":"Virus Evol"},{"key":"e_1_3_4_4_2","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2019.04.032","article-title":"Ononin, sec-O-\u03b2-d-glucosylhamaudol and astragaloside I: Antiviral lead compounds identified via high throughput screening and biological validation from traditional Chinese medicine Zhongjing formulary","volume":"145","author":"Yu Y","year":"2019","unstructured":"Yu Y, Li Z, Guo R, Qian J, Zhang H, Zhang J, Zhao X, Wang S, Wang Y. Ononin, sec-O-\u03b2-d-glucosylhamaudol and astragaloside I: Antiviral lead compounds identified via high throughput screening and biological validation from traditional Chinese medicine Zhongjing formulary. Pharmacol Res. 2019;145: Article 104248.","journal-title":"Pharmacol Res"},{"issue":"5","key":"e_1_3_4_5_2","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1186\/gb-2010-11-5-206","article-title":"Between a chicken and a grape: Estimating the number of human genes","volume":"11","author":"Pertea M","year":"2010","unstructured":"Pertea M, Salzberg SL. Between a chicken and a grape: Estimating the number of human genes. Genome Biol. 2010;11(5):206.","journal-title":"Genome Biol"},{"issue":"5","key":"e_1_3_4_6_2","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a038687","article-title":"Influenza polymerase inhibitors: Mechanisms of action and resistance","volume":"11","author":"Takashita E","year":"2021","unstructured":"Takashita E. Influenza polymerase inhibitors: Mechanisms of action and resistance. Cold Spring Harb Perspect Med. 2021;11(5): Article a038687.","journal-title":"Cold Spring Harb Perspect Med"},{"key":"e_1_3_4_7_2","doi-asserted-by":"crossref","DOI":"10.1177\/20587384211002621","article-title":"A review: Mechanism of action of antiviral drugs","volume":"35","author":"Kausar S","year":"2021","unstructured":"Kausar S, Said Khan F, Ishaq Mujeeb Ur Rehman M, Akram M, Riaz M, Rasool G, Hamid Khan A, Saleem I, Shamim S, Malik A. A review: Mechanism of action of antiviral drugs. Int J Immunopathol Pharmacol. 2021;35: Article 20587384211002621.","journal-title":"Int J Immunopathol Pharmacol"},{"issue":"30","key":"e_1_3_4_8_2","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adl4013","article-title":"In vitro selection and analysis of SARS-CoV-2 nirmatrelvir resistance mutations contributing to clinical virus resistance surveillance","volume":"10","author":"Zhu Y","year":"2024","unstructured":"Zhu Y, Yurgelonis I, Noell S, Yang Q, Guan S, Li Z, Hao L, Rothan H, Rai DK, McMonagle P, et al. In vitro selection and analysis of SARS-CoV-2 nirmatrelvir resistance mutations contributing to clinical virus resistance surveillance. Sci Adv. 2024;10(30): Article eadl4013.","journal-title":"Sci Adv"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtn.2023.03.013"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2022.09.010"},{"issue":"2","key":"e_1_3_4_11_2","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.idc.2010.01.001","article-title":"Antiviral drug resistance: Mechanisms and clinical implications","volume":"24","author":"Strasfeld L","year":"2010","unstructured":"Strasfeld L, Chou S. Antiviral drug resistance: Mechanisms and clinical implications. Infect Dis Clin North Am. 2010;24(2):413\u2013437.","journal-title":"Infect Dis Clin North Am"},{"issue":"1","key":"e_1_3_4_12_2","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1038\/s44259-025-00125-z","article-title":"Strategies and efforts in circumventing the emergence of antiviral resistance against conventional antivirals","volume":"3","author":"Aw DZH","year":"2025","unstructured":"Aw DZH, Zhang DX, Vignuzzi M. Strategies and efforts in circumventing the emergence of antiviral resistance against conventional antivirals. NPJ Antimicrob Resist. 2025;3(1):54.","journal-title":"NPJ Antimicrob Resist"},{"issue":"8","key":"e_1_3_4_13_2","doi-asserted-by":"crossref","DOI":"10.1128\/jcm.00728-23","article-title":"Practical updates in clinical antiviral resistance testing","volume":"62","author":"Wang H","year":"2024","unstructured":"Wang H. Practical updates in clinical antiviral resistance testing. J Clin Microbiol. 2024;62(8): Article e0072823.","journal-title":"J Clin Microbiol"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.3390\/pathogens14010020"},{"issue":"738","key":"e_1_3_4_15_2","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adi0979","article-title":"An orally bioavailable SARS-CoV-2 main protease inhibitor exhibits improved affinity and reduced sensitivity to mutations","volume":"16","author":"Westberg M","year":"2024","unstructured":"Westberg M, Su Y, Zou X, Huang P, Rustagi A, Garhyan J, Patel PB, Fernandez D, Wu Y, Hao C, et al. An orally bioavailable SARS-CoV-2 main protease inhibitor exhibits improved affinity and reduced sensitivity to mutations. Sci Transl Med. 2024;16(738): Article eadi0979.","journal-title":"Sci Transl Med"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.3390\/v17081064"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.abl4784"},{"issue":"11","key":"e_1_3_4_18_2","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMc2206449","article-title":"Rebound of SARS-CoV-2 infection after nirmatrelvir\u2013ritonavir treatment","volume":"387","author":"Charness ME","year":"2022","unstructured":"Charness ME, Gupta K, Stack G, Strymish J, Adams E, Lindy DC, Mohri H, Ho DD. Rebound of SARS-CoV-2 infection after nirmatrelvir\u2013ritonavir treatment. N Engl J Med. 2022;387(11):1045\u20131047.","journal-title":"N Engl J Med"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-022-05514-2"},{"issue":"1","key":"e_1_3_4_20_2","doi-asserted-by":"crossref","first-page":"3952","DOI":"10.1038\/s41467-023-39704-x","article-title":"In vitro and in\u00a0vivo characterization of SARS-CoV-2 strains resistant to nirmatrelvir","volume":"14","author":"Kiso M","year":"2023","unstructured":"Kiso M, Furusawa Y, Uraki R, Imai M, Yamayoshi S, Kawaoka Y. In vitro and in\u00a0vivo characterization of SARS-CoV-2 strains resistant to nirmatrelvir. Nat Commun. 2023;14(1):3952.","journal-title":"Nat Commun"},{"key":"e_1_3_4_21_2","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2024.106022","article-title":"Replication capacity and susceptibility of nirmatrelvir-resistant mutants to next-generation Mpro inhibitors in a SARS-CoV-2 replicon system","volume":"231","author":"Lo C-W","year":"2024","unstructured":"Lo C-W, Kariv O, Hao C, Gammeltoft KA, Bukh J, Gottwein J, Westberg M, Lin MZ, Einav S. Replication capacity and susceptibility of nirmatrelvir-resistant mutants to next-generation Mpro inhibitors in a SARS-CoV-2 replicon system. Antiviral Res. 2024;231: Article 106022.","journal-title":"Antiviral Res"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1021\/acsbiomedchemau.4c00045"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.chom.2021.01.014"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.3390\/ph15040396"},{"key":"e_1_3_4_25_2","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.113850","article-title":"Assessing the potential of repurposing ion channel inhibitors to treat emerging viral diseases and the role of this host factor in virus replication","volume":"156","author":"Russell T","year":"2022","unstructured":"Russell T, Gangotia D, Barry G. Assessing the potential of repurposing ion channel inhibitors to treat emerging viral diseases and the role of this host factor in virus replication. Biomed Pharmacother. 2022;156: Article 113850.","journal-title":"Biomed Pharmacother"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.coviro.2020.07.001"},{"key":"e_1_3_4_27_2","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/j.ijbiomac.2020.12.142","article-title":"SARS-Cov-2 ORF3a: Mutability and function","volume":"170","author":"Bianchi M","year":"2021","unstructured":"Bianchi M, Borsetti A, Ciccozzi M, Pascarella S. SARS-Cov-2 ORF3a: Mutability and function. Int J Biol Macromol. 2021;170:820\u2013826.","journal-title":"Int J Biol Macromol"},{"issue":"3","key":"e_1_3_4_28_2","doi-asserted-by":"crossref","DOI":"10.1128\/msystems.00266-20","article-title":"SARS-CoV-2 and ORF3a: Nonsynonymous mutations, functional domains, and viral pathogenesis","volume":"5","author":"Issa E","year":"2020","unstructured":"Issa E, Merhi G, Panossian B, Salloum T, Tokajian S. SARS-CoV-2 and ORF3a: Nonsynonymous mutations, functional domains, and viral pathogenesis. mSystems. 2020;5(3): Article e00266-20.","journal-title":"mSystems"},{"issue":"1","key":"e_1_3_4_29_2","doi-asserted-by":"crossref","DOI":"10.1002\/pro.4528","article-title":"Exhaustive mutational analysis of severe acute respiratory syndrome coronavirus 2 ORF3a: An essential component in the pathogen\u2019s infectivity cycle","volume":"32","author":"Benazraf A","year":"2023","unstructured":"Benazraf A, Arkin IT. Exhaustive mutational analysis of severe acute respiratory syndrome coronavirus 2 ORF3a: An essential component in the pathogen\u2019s infectivity cycle. Protein Sci. 2023;32(1): Article e4528.","journal-title":"Protein Sci"},{"issue":"8","key":"e_1_3_4_30_2","doi-asserted-by":"crossref","first-page":"4011","DOI":"10.1021\/acs.jcim.1c00488","article-title":"Determination of ligand binding modes in hydrated viral ion channels to foster drug design and repositioning","volume":"61","author":"Zsid\u00f3 BZ","year":"2021","unstructured":"Zsid\u00f3 BZ, B\u00f6rzsei R, Sz\u00e9l V, Het\u00e9nyi C. Determination of ligand binding modes in hydrated viral ion channels to foster drug design and repositioning. J Chem Inf Model. 2021;61(8):4011\u20134022.","journal-title":"J Chem Inf Model"},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.1021\/jacs.8b06741"},{"issue":"6","key":"e_1_3_4_32_2","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/j.ejmech.2011.01.047","article-title":"The many faces of the adamantyl group in drug design","volume":"46","author":"Liu J","year":"2011","unstructured":"Liu J, Obando D, Liao V, Lifa T, Codd R. The many faces of the adamantyl group in drug design. Eur J Med Chem. 2011;46(6):1949\u20131963.","journal-title":"Eur J Med Chem"},{"key":"e_1_3_4_33_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41594-020-00536-8"},{"key":"e_1_3_4_34_2","doi-asserted-by":"publisher","DOI":"10.3390\/v14030640"},{"issue":"4","key":"e_1_3_4_35_2","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1107\/S2059798321001431","article-title":"Structural biology of coronavirus ion channels","volume":"77","author":"Barrantes FJ","year":"2021","unstructured":"Barrantes FJ. Structural biology of coronavirus ion channels. Acta Crystallogr D Struct Biol. 2021;77(Pt 4):391\u2013402.","journal-title":"Acta Crystallogr D Struct Biol"},{"issue":"1","key":"e_1_3_4_36_2","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/s41421-023-00575-7","article-title":"Impact of SARS-CoV-2 envelope protein mutations on the pathogenicity of omicron XBB","volume":"9","author":"Wang Y","year":"2023","unstructured":"Wang Y, Pan X, Ji H, Zuo X, Xiao G-F, Li J, Zhang L-K, Xia B, Gao Z. Impact of SARS-CoV-2 envelope protein mutations on the pathogenicity of omicron XBB. Cell Discov. 2023;9(1):80.","journal-title":"Cell Discov"},{"key":"e_1_3_4_37_2","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1090717","article-title":"Variant-specific deleterious mutations in the SARS-CoV-2 genome reveal immune responses and potentials for prophylactic vaccine development","volume":"14","author":"Islam MA","year":"2023","unstructured":"Islam MA, Shahi S, Marzan AA, Amin MR, Hasan MN, Hoque MN, Ghosh A, Barua A, Khan A, Dhama K, et al. Variant-specific deleterious mutations in the SARS-CoV-2 genome reveal immune responses and potentials for prophylactic vaccine development. Front Pharmacol. 2023;14: Article 1090717.","journal-title":"Front Pharmacol"},{"key":"e_1_3_4_38_2","doi-asserted-by":"publisher","DOI":"10.3390\/molecules22020297"},{"key":"e_1_3_4_39_2","doi-asserted-by":"publisher","DOI":"10.1021\/cr100264t"},{"key":"e_1_3_4_40_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM196909112811102"},{"key":"e_1_3_4_41_2","doi-asserted-by":"publisher","DOI":"10.1110\/ps.062730007"},{"key":"e_1_3_4_42_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.csbj.2025.06.036"},{"key":"e_1_3_4_43_2","doi-asserted-by":"publisher","DOI":"10.3390\/v13040539"},{"issue":"11","key":"e_1_3_4_44_2","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.3390\/covid2110111","article-title":"Anti-SARS-CoV-2 activity of adamantanes in\u00a0vitro and in animal models of infection","volume":"2","author":"Lim SY","year":"2022","unstructured":"Lim SY, Guo Z, Liu P, McKay LG, Storm N, Griffiths A, Qu MD, Finberg RW, Somasundaran M, Wang JP. Anti-SARS-CoV-2 activity of adamantanes in\u00a0vitro and in animal models of infection. COVID. 2022;2(11):1551\u20131563.","journal-title":"COVID"},{"issue":"3","key":"e_1_3_4_45_2","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s40268-021-00351-6","article-title":"Potential for the repurposing of adamantane antivirals for COVID-19","volume":"21","author":"Butterworth RF","year":"2021","unstructured":"Butterworth RF. Potential for the repurposing of adamantane antivirals for COVID-19. Drugs R D. 2021;21(3):267\u2013272.","journal-title":"Drugs R D"},{"issue":"1","key":"e_1_3_4_46_2","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1038\/s42003-021-02940-2","article-title":"Amantadine inhibits known and novel ion channels encoded by SARS-CoV-2 in\u00a0vitro","volume":"4","author":"Toft-Bertelsen TL","year":"2021","unstructured":"Toft-Bertelsen TL, Jeppesen MG, Tzortzini E, Xue K, Giller K, Becker S, Mujezinovic A, Bentzen BH, Andreas LB, Kolocouris A, et al. Amantadine inhibits known and novel ion channels encoded by SARS-CoV-2 in\u00a0vitro. Commun Biol. 2021;4(1):1402.","journal-title":"Commun Biol"},{"issue":"10","key":"e_1_3_4_47_2","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.3390\/v13102082","article-title":"Efficacy of ion-channel inhibitors amantadine, memantine and rimantadine for the treatment of SARS-CoV-2 in\u00a0vitro","volume":"13","author":"Zhou Y","year":"2021","unstructured":"Zhou Y, Gammeltoft KA, Galli A, Offersgaard A, Fahn\u00f8e U, Ramirez S, Bukh J, Gottwein JM. Efficacy of ion-channel inhibitors amantadine, memantine and rimantadine for the treatment of SARS-CoV-2 in\u00a0vitro. Viruses. 2021;13(10):2082.","journal-title":"Viruses"},{"issue":"18","key":"e_1_3_4_48_2","doi-asserted-by":"crossref","DOI":"10.1128\/jvi.00646-22","article-title":"Amantadine and rimantadine inhibit hepatitis A virus replication through the induction of autophagy","volume":"96","author":"Sasaki-Tanaka R","year":"2022","unstructured":"Sasaki-Tanaka R, Shibata T, Moriyama M, Okamoto H, Kogure H, Kanda T. Amantadine and rimantadine inhibit hepatitis A virus replication through the induction of autophagy. J Virol. 2022;96(18): Article e0064622.","journal-title":"J Virol"},{"key":"e_1_3_4_49_2","doi-asserted-by":"crossref","DOI":"10.1016\/j.cct.2022.106755","article-title":"The use of amantadine in the prevention of progression and treatment of COVID-19 symptoms in patients infected with the SARS-CoV-2 virus (COV-PREVENT): Study rationale and design","volume":"116","author":"Rejdak K","year":"2022","unstructured":"Rejdak K, Fiedor P, Bonek R, Goch A, Gala-B\u0142\u0105dzi\u0144ska A, Che\u0142stowski W, \u0141ukasiak J, Kiciak S, D\u0105browski P, Dec M, et al. The use of amantadine in the prevention of progression and treatment of COVID-19 symptoms in patients infected with the SARS-CoV-2 virus (COV-PREVENT): Study rationale and design. Contemp Clin Trials. 2022;116: Article 106755.","journal-title":"Contemp Clin Trials"},{"issue":"1","key":"e_1_3_4_50_2","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1002\/jmv.26179","article-title":"Use of amantadine in a patient with SARS-CoV-2","volume":"93","author":"Aranda-Abreu GE","year":"2021","unstructured":"Aranda-Abreu GE, Aranda-Mart\u00ednez JD, Ara\u00fajo R. Use of amantadine in a patient with SARS-CoV-2. J Med Virol. 2021;93(1):110\u2013111.","journal-title":"J Med Virol"},{"issue":"2","key":"e_1_3_4_51_2","doi-asserted-by":"crossref","first-page":"100","DOI":"10.36959\/719\/575","article-title":"Protective effect of amantadine in a COVID-19 patient: Case report","volume":"3","author":"Albert Cort\u00e9s B","year":"2020","unstructured":"Albert Cort\u00e9s B. Protective effect of amantadine in a COVID-19 patient: Case report. Res Rev Infect Dis. 2020;3(2):100\u2013101.","journal-title":"Res Rev Infect Dis"},{"key":"e_1_3_4_52_2","doi-asserted-by":"crossref","DOI":"10.1016\/j.virusres.2023.199291","article-title":"New anti-SARS-CoV-2 aminoadamantane compounds as antiviral candidates for the treatment of COVID-19","volume":"340","author":"Almeida Marques DP","year":"2024","unstructured":"de Almeida Marques DP, Andrade LA, Reis EV, Clarindo FA, Moraes TD, Louren\u00e7o KL, De Barros WA, Costa NE, de Andrade LM, Lopes-Ribeiro \u00c1, et al. New anti-SARS-CoV-2 aminoadamantane compounds as antiviral candidates for the treatment of COVID-19. Virus Res. 2024;340: Article 199291.","journal-title":"Virus Res"},{"issue":"1","key":"e_1_3_4_53_2","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1038\/s41598-024-51904-z","article-title":"A randomized open-label clinical trial on the effect of amantadine on post Covid 19 fatigue","volume":"14","author":"Harandi AA","year":"2024","unstructured":"Harandi AA, Pakdaman H, Medghalchi A, Kimia N, Kazemian A, Siavoshi F, Barough SS, Esfandani A, Hosseini MH, Sobhanian SA. A randomized open-label clinical trial on the effect of amantadine on post Covid 19 fatigue. Sci Rep. 2024;14(1):1343.","journal-title":"Sci Rep"},{"key":"e_1_3_4_54_2","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2023.107198","article-title":"Efficacy of oral amantadine among patients hospitalised with COVID-19: A randomised, double-blind, placebo-controlled, multicentre study","volume":"212","author":"Barczyk A","year":"2023","unstructured":"Barczyk A, Czajkowska-Malinowska M, Farnik M, Barczyk M, Boda \u0141, Cofta S, Du\u0142awa J, Dyrbu\u015b M, Harat R, Huk M, et al. Efficacy of oral amantadine among patients hospitalised with COVID-19: A randomised, double-blind, placebo-controlled, multicentre study. Respir Med. 2023;212: Article 107198.","journal-title":"Respir Med"},{"key":"e_1_3_4_55_2","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.ijid.2022.09.026","article-title":"Improved survival in intensive care unit in severe COVID-19 associated with amantadine use\u2014Retrospective study","volume":"124","author":"Chober D","year":"2022","unstructured":"Chober D, Czajkowski Z, Aksak-W\u0105s B, Dalewska-Kucharczyk K, Ho\u0142ubczak K, Karasi\u0144ska-Milchert S, Jaremko M, Skowron M, Karasi\u0144ska-Cie\u015blak M, Parczewski M. Improved survival in intensive care unit in severe COVID-19 associated with amantadine use\u2014Retrospective study. Int J Infect Dis. 2022;124:143\u2013151.","journal-title":"Int J Infect Dis"},{"issue":"1","key":"e_1_3_4_56_2","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.bbrc.2020.05.206","article-title":"SARS-CoV-2 E protein is a potential ion channel that can be inhibited by gliclazide and memantine","volume":"530","author":"Singh Tomar PP","year":"2020","unstructured":"Singh Tomar PP, Arkin IT. SARS-CoV-2 E protein is a potential ion channel that can be inhibited by gliclazide and memantine. Biochem Biophys Res Commun. 2020;530(1):10\u201314.","journal-title":"Biochem Biophys Res Commun"},{"key":"e_1_3_4_57_2","doi-asserted-by":"publisher","DOI":"10.3390\/biom12111673"},{"key":"e_1_3_4_58_2","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2021.692423","article-title":"Inhibition of SARS CoV envelope protein by flavonoids and classical viroporin inhibitors","volume":"12","author":"Breitinger U","year":"2021","unstructured":"Breitinger U, Ali NKM, Sticht H, Breitinger H-G. Inhibition of SARS CoV envelope protein by flavonoids and classical viroporin inhibitors. Front Microbiol. 2021;12: Article 692423.","journal-title":"Front Microbiol"},{"issue":"1","key":"e_1_3_4_59_2","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1186\/s12985-023-02095-y","article-title":"Patch-clamp studies and cell viability assays suggest a distinct site for viroporin inhibitors on the E protein of SARS-CoV-2","volume":"20","author":"Breitinger U","year":"2023","unstructured":"Breitinger U, Sedky CA, Sticht H, Breitinger H-G. Patch-clamp studies and cell viability assays suggest a distinct site for viroporin inhibitors on the E protein of SARS-CoV-2. Virol J. 2023;20(1):142.","journal-title":"Virol J"},{"issue":"5","key":"e_1_3_4_60_2","doi-asserted-by":"crossref","DOI":"10.1128\/jvi.02252-24","article-title":"A BSL-2 chimeric system designed to screen SARS-CoV-2 E protein ion channel inhibitors","volume":"99","author":"Negi V","year":"2025","unstructured":"Negi V, Kuhn RJ. A BSL-2 chimeric system designed to screen SARS-CoV-2 E protein ion channel inhibitors. J Virol. 2025;99(5): Article e0225224.","journal-title":"J Virol"},{"key":"e_1_3_4_61_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.csbj.2024.10.021"},{"key":"e_1_3_4_62_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.csbj.2025.04.042"},{"key":"e_1_3_4_63_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.csbj.2024.10.030"},{"key":"e_1_3_4_64_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.csbj.2025.08.031"},{"key":"e_1_3_4_65_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.csbj.2025.08.006"},{"key":"e_1_3_4_66_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.csbj.2024.11.048"},{"key":"e_1_3_4_67_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.csbj.2023.12.028"},{"key":"e_1_3_4_68_2","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.104761","article-title":"Lianhuaqingwen exerts anti-viral and anti-inflammatory activity against novel coronavirus (SARS-CoV-2)","volume":"156","author":"Runfeng L","year":"2020","unstructured":"Runfeng L, Yunlong H, Jicheng H, Weiqi P, Qinhai M, Yongxia S, Chufang L, Jin Z, Zhenhua J, Haiming J, et al. Lianhuaqingwen exerts anti-viral and anti-inflammatory activity against novel coronavirus (SARS-CoV-2). Pharmacol Res. 2020;156: Article 104761.","journal-title":"Pharmacol Res"},{"key":"e_1_3_4_69_2","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.117592","article-title":"The adamantane scaffold: Beyond a lipophilic moiety","volume":"291","author":"Dane C","year":"2025","unstructured":"Dane C, Montgomery AP, Kassiou M. The adamantane scaffold: Beyond a lipophilic moiety. Eur J Med Chem. 2025;291: Article 117592.","journal-title":"Eur J Med Chem"},{"issue":"46","key":"e_1_3_4_70_2","doi-asserted-by":"crossref","first-page":"31714","DOI":"10.1039\/D3CP04483A","article-title":"Target\u2013ligand binding affinity from single point enthalpy calculation and elemental composition","volume":"25","author":"Sz\u00e9l V","year":"2023","unstructured":"Sz\u00e9l V, Zsid\u00f3 BZ, Jeszen\u0151i N, Het\u00e9nyi C. Target\u2013ligand binding affinity from single point enthalpy calculation and elemental composition. Phys Chem Chem Phys. 2023;25(46):31714\u201331725.","journal-title":"Phys Chem Chem Phys"},{"key":"e_1_3_4_71_2","doi-asserted-by":"publisher","DOI":"10.1080\/17460441.2025.2497912"},{"key":"e_1_3_4_72_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.sbi.2020.08.002","article-title":"The role of water in ligand binding","volume":"67","author":"Zsid\u00f3 BZ","year":"2021","unstructured":"Zsid\u00f3 BZ, Het\u00e9nyi C. The role of water in ligand binding. Curr Opin Struct Biol. 2021;67:1\u20138.","journal-title":"Curr Opin Struct Biol"},{"issue":"5","key":"e_1_3_4_73_2","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1016\/j.febslet.2006.01.074","article-title":"Blind docking of drug-sized compounds to proteins with up to a thousand residues","volume":"580","author":"Het\u00e9nyi C","year":"2006","unstructured":"Het\u00e9nyi C, Van Der Spoel D. Blind docking of drug-sized compounds to proteins with up to a thousand residues. FEBS Lett. 2006;580(5):1447\u20131450.","journal-title":"FEBS Lett"},{"key":"e_1_3_4_74_2","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2026.109949","article-title":"In silico characterisation of a novel SARS-CoV-2 envelope protein inhibitor and in\u00a0vitro validation against murine coronavirus","volume":"178","author":"Kobe N","year":"2026","unstructured":"Kobe N, Dreisewerd L, Luk\u0161i\u010d M, Pavlin M, Gro\u0161elj U, Podlipnik \u010c, Janc M, Lengar \u017d, Mrak P, \u017dnidari\u010d MT, et al. In silico characterisation of a novel SARS-CoV-2 envelope protein inhibitor and in\u00a0vitro validation against murine coronavirus. Bioorg Chem. 2026;178: Article 109949.","journal-title":"Bioorg Chem"},{"key":"e_1_3_4_75_2","doi-asserted-by":"publisher","DOI":"10.1080\/17460441.2024.2349169"},{"key":"e_1_3_4_76_2","doi-asserted-by":"crossref","DOI":"10.1016\/j.sbi.2024.102870","article-title":"Quantum mechanical-based strategies in drug discovery: Finding the pace to new challenges in drug design","volume":"87","author":"Ginex T","year":"2024","unstructured":"Ginex T, V\u00e1zquez J, Estarellas C, Luque FJ. Quantum mechanical-based strategies in drug discovery: Finding the pace to new challenges in drug design. Curr Opin Struct Biol. 2024;87: Article 102870.","journal-title":"Curr Opin Struct Biol"},{"issue":"14","key":"e_1_3_4_77_2","doi-asserted-by":"crossref","first-page":"11784","DOI":"10.3390\/ijms241411784","article-title":"The advances and limitations of the determination and applications of water structure in molecular engineering","volume":"24","author":"Zsid\u00f3 BZ","year":"2023","unstructured":"Zsid\u00f3 BZ, Bayarsaikhan B, B\u00f6rzsei R, Sz\u00e9l V, Mohos V, Het\u00e9nyi C. The advances and limitations of the determination and applications of water structure in molecular engineering. Int J Mol Sci. 2023;24(14):11784.","journal-title":"Int J Mol Sci"},{"issue":"10","key":"e_1_3_4_78_2","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/S1359-6446(04)03069-7","article-title":"Ligand efficiency: A useful metric for lead selection","volume":"9","author":"Hopkins AL","year":"2004","unstructured":"Hopkins AL, Groom CR, Alex A. Ligand efficiency: A useful metric for lead selection. Drug Discov Today. 2004;9(10):430\u2013431.","journal-title":"Drug Discov Today"},{"issue":"2","key":"e_1_3_4_79_2","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/nrd4163","article-title":"The role of ligand efficiency metrics in drug discovery","volume":"13","author":"Hopkins AL","year":"2014","unstructured":"Hopkins AL, Keser\u00fc GM, Leeson PD, Rees DC, Reynolds CH. The role of ligand efficiency metrics in drug discovery. Nat Rev Drug Discov. 2014;13(2):105\u2013121.","journal-title":"Nat Rev Drug Discov"},{"key":"e_1_3_4_80_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(20)30929-4"},{"issue":"1","key":"e_1_3_4_81_2","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/0022-1759(83)90303-4","article-title":"Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays","volume":"65","author":"Mosmann T","year":"1983","unstructured":"Mosmann T. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J Immunol Methods. 1983;65(1\u20132):55\u201363.","journal-title":"J Immunol Methods"},{"issue":"1","key":"e_1_3_4_82_2","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.jviromet.2006.01.022","article-title":"A colorimetric assay for viral agents that produce cytopathic effects","volume":"135","author":"Heldt CL","year":"2006","unstructured":"Heldt CL, Hernandez R, Mudiganti U, Gurgel PV, Brown DT, Carbonell RG. A colorimetric assay for viral agents that produce cytopathic effects. J Virol Methods. 2006;135(1):56\u201365.","journal-title":"J Virol Methods"},{"issue":"7","key":"e_1_3_4_83_2","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1021\/acsinfecdis.1c00053","article-title":"Inhibition of human coronaviruses by antimalarial peroxides","volume":"7","author":"Ghosh AK","year":"2021","unstructured":"Ghosh AK, Miller H, Knox K, Kundu M, Henrickson KJ, Arav-Boger R. Inhibition of human coronaviruses by antimalarial peroxides. ACS Infect Dis. 2021;7(7):1985\u20131995.","journal-title":"ACS Infect Dis"},{"issue":"3","key":"e_1_3_4_84_2","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1021\/acsmedchemlett.7b00458","article-title":"Unraveling the binding, proton blockage, and inhibition of influenza M2 WT and S31N by rimantadine variants","volume":"9","author":"Drakopoulos A","year":"2018","unstructured":"Drakopoulos A, Tzitzoglaki C, McGuire K, Hoffmann A, Konstantinidi A, Kolokouris D, Ma C, Freudenberger K, Hutterer J, Gauglitz G, et al. Unraveling the binding, proton blockage, and inhibition of influenza M2 WT and S31N by rimantadine variants. ACS Med Chem Lett. 2018;9(3):198\u2013203.","journal-title":"ACS Med Chem Lett"},{"key":"e_1_3_4_85_2","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2023.105758","article-title":"A phenothiazine urea derivative broadly inhibits coronavirus replication via viral protease inhibition","volume":"220","author":"Forrestall K","year":"2023","unstructured":"Forrestall K, Pringle ES, Sands D, Duguay BA, Farewell B, Woldemariam T, Falzarano D, Pottie I, McCormick C, Darvesh S. A phenothiazine urea derivative broadly inhibits coronavirus replication via viral protease inhibition. Antiviral Res. 2023;220: Article 105758.","journal-title":"Antiviral Res"},{"issue":"1","key":"e_1_3_4_86_2","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1021\/acs.jmedchem.7b00908","article-title":"Aniline-based inhibitors of influenza H1N1 virus acting on hemagglutinin-mediated fusion","volume":"61","author":"Leiva R","year":"2018","unstructured":"Leiva R, Barniol-Xicota M, Codony S, Ginex T, Vanderlinden E, Montes M, Caffrey M, Luque FJ, Naesens L, V\u00e1zquez S. Aniline-based inhibitors of influenza H1N1 virus acting on hemagglutinin-mediated fusion. J Med Chem. 2018;61(1):98\u2013118.","journal-title":"J Med Chem"},{"issue":"19","key":"e_1_3_4_87_2","doi-asserted-by":"crossref","first-page":"5513","DOI":"10.1016\/j.bmc.2014.07.020","article-title":"Synthesis and structure\u2013activity relationships of novel, potent, orally active hypoxia-inducible factor-1 inhibitors","volume":"22","author":"Nagao S","year":"2014","unstructured":"Nagao S, Yamane Y, Funasaka S, Tanaka K, Miyazaki K, Kotake Y, Kamata JI, Watanabe-Miyano S, Toyama O, Ozawa Y, et al. Synthesis and structure\u2013activity relationships of novel, potent, orally active hypoxia-inducible factor-1 inhibitors. Bioorg Med Chem. 2014;22(19):5513\u20135529.","journal-title":"Bioorg Med Chem"},{"key":"e_1_3_4_88_2","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s12936-015-0572-z","article-title":"A novel inhibitor of Plasmodium falciparum spermidine synthase: A twist in the tail","volume":"14","author":"Burger PB","year":"2015","unstructured":"Burger PB, Williams M, Sprenger J, Reeksting SB, Botha M, M\u00fcller IB, Joubert F, Birkholtz L-M, Louw AI. A novel inhibitor of Plasmodium falciparum spermidine synthase: A twist in the tail. Malar J. 2015;14:54.","journal-title":"Malar J"},{"issue":"19","key":"e_1_3_4_89_2","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1056\/NEJMoa2001282","article-title":"A trial of lopinavir\u2013ritonavir in adults hospitalized with severe Covid-19","volume":"382","author":"Cao B","year":"2020","unstructured":"Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, Ruan L, Song B, Cai Y, Wei M, et al. A trial of lopinavir\u2013ritonavir in adults hospitalized with severe Covid-19. N Engl J Med. 2020;382(19):1787\u20131799.","journal-title":"N Engl J Med"},{"key":"e_1_3_4_90_2","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jcim.4c00794"},{"issue":"6","key":"e_1_3_4_91_2","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1107\/S0907444902003451","article-title":"The Protein Data Bank","volume":"58","author":"Berman HM","year":"2002","unstructured":"Berman HM, Battistuz T, Bhat TN, Bluhm WF, Bourne PE, Burkhardt K, Feng Z, Gilliland GL, Iype L, Jain S, et al. The Protein Data Bank. Acta Crystallogr D Biol Crystallogr. 2002;58(6):899\u2013907.","journal-title":"Acta Crystallogr D Biol Crystallogr"},{"key":"e_1_3_4_92_2","unstructured":"Schr\u00f6dinger Release 2024-1. Maestro. New York (NY): Schr\u00f6dinger LLC; 2024."},{"key":"e_1_3_4_93_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20020422"},{"issue":"16","key":"e_1_3_4_94_2","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.1002\/jcc.21256","article-title":"AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility","volume":"30","author":"Morris GM","year":"2009","unstructured":"Morris GM, Huey R, Lindstrom W, Sanner MF, Belew RK, Goodsell DS, Olson AJ. AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. J Comput Chem. 2009;30(16):2785\u20132791.","journal-title":"J Comput Chem"},{"key":"e_1_3_4_95_2","doi-asserted-by":"publisher","DOI":"10.1186\/1758-2946-3-33"},{"issue":"10","key":"e_1_3_4_96_2","first-page":"1545","article-title":"CHARMM: Molecular dynamics simulation package","volume":"30","author":"Brooks BR","year":"2009","unstructured":"Brooks BR, Brooks CL, Mackerell AD, Nilsson L, Petrella RJ, Roux B, Won Y, Archontis G, Bartels C, Boresch S, et al. CHARMM: Molecular dynamics simulation package. J Comput Chem. 2009;30(10):1545\u20131614.","journal-title":"J Comput Chem"},{"issue":"12","key":"e_1_3_4_97_2","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1093\/bioinformatics\/btv093","article-title":"Mobility-based prediction of hydration structures of protein surfaces","volume":"31","author":"Jeszen\u0151i N","year":"2015","unstructured":"Jeszen\u0151i N, Horv\u00e1th I, B\u00e1lint M, Van Der Spoel D, Het\u00e9nyi C. Mobility-based prediction of hydration structures of protein surfaces. Bioinformatics. 2015;31(12):1959\u20131965.","journal-title":"Bioinformatics"},{"issue":"9","key":"e_1_3_4_98_2","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1002\/jcc.20035","article-title":"Development and testing of a general Amber force field","volume":"25","author":"Wang J","year":"2004","unstructured":"Wang J, Wolf RM, Caldwell JW, Kollman PA, Case DA. Development and testing of a general Amber force field. J Comput Chem. 2004;25(9):1157\u20131174.","journal-title":"J Comput Chem"},{"issue":"8","key":"e_1_3_4_99_2","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1093\/protein\/4.8.903","article-title":"Electrostatic effects in proteins: Comparison of dielectric and charge models","volume":"4","author":"Mehler EL","year":"1991","unstructured":"Mehler EL, Solmajer T. Electrostatic effects in proteins: Comparison of dielectric and charge models. Protein Eng Des Sel. 1991;4(8):903\u2013910.","journal-title":"Protein Eng Des Sel"},{"key":"e_1_3_4_100_2","unstructured":"Stewart JJ Klamt A Thiel W Danovich D Rocha GB Gieseking RL Moussa JE Kurtz HA Korambath P Merz KM et\u00a0al. MOPAC (22.0.0). 2022. https:\/\/Doi.Org\/10.5281\/Zenodo.6511959"},{"key":"e_1_3_4_101_2","doi-asserted-by":"publisher","DOI":"10.1099\/jgv.0.001453"},{"issue":"1","key":"e_1_3_4_102_2","doi-asserted-by":"crossref","first-page":"D20","DOI":"10.1093\/nar\/gkae979","article-title":"Database resources of the National Center for Biotechnology Information in 2025","volume":"53","author":"Sayers EW","year":"2025","unstructured":"Sayers EW, Beck J, Bolton EE, Brister JR, Chan J, Connor R, Feldgarden M, Fine AM, Funk K, Hoffman J, et al. Database resources of the National Center for Biotechnology Information in 2025. Nucleic Acids Res. 2025;53(D1):D20\u2013D29.","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"e_1_3_4_103_2","doi-asserted-by":"crossref","first-page":"W521","DOI":"10.1093\/nar\/gkae241","article-title":"The EMBL-EBI job dispatcher sequence analysis tools framework in 2024","volume":"52","author":"Madeira F","year":"2024","unstructured":"Madeira F, Madhusoodanan N, Lee J, Eusebi A, Niewielska A, Tivey ARN, Lopez R, Butcher S. The EMBL-EBI job dispatcher sequence analysis tools framework in 2024. Nucleic Acids Res. 2024;52(W1):W521\u2013W525.","journal-title":"Nucleic Acids Res"}],"container-title":["Computational and Structural Biotechnology Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/spj.science.org\/doi\/pdf\/10.34133\/csbj.0188","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T12:54:35Z","timestamp":1785761675000},"score":1,"resource":{"primary":{"URL":"https:\/\/spj.science.org\/doi\/10.34133\/csbj.0188"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,1]]},"references-count":102,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,3,1]]}},"alternative-id":["10.34133\/csbj.0188"],"URL":"https:\/\/doi.org\/10.34133\/csbj.0188","relation":{},"ISSN":["2001-0370"],"issn-type":[{"value":"2001-0370","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,1]]},"assertion":[{"value":"2026-05-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-10","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-13","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-03","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"0188"}}